Santafe News Online

Spinal Muscular Atrophy (SMA) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Spinal Muscular Atrophy (SMA) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 25
13:50 2020
Spinal Muscular Atrophy (SMA) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

DelveInsight has launched a new report on Spinal Muscular Atrophy Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Spinal Muscular Atrophy (SMA) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Spinal Muscular Atrophy (SMA), historical and forecasted epidemiology as well as the Spinal Muscular Atrophy (SMA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spinal Muscular Atrophy (SMA) market report provides current treatment practices, emerging drugs, Spinal Muscular Atrophy (SMA) market share of the individual therapies, current and forecasted Spinal Muscular Atrophy (SMA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Spinal Muscular Atrophy (SMA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

According to National Institute of Health (NIH), Spinal muscular atrophy is a genetic disorder characterized

by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body’s center (distal). The muscle weakness usually worsens with age. SMA is a motor neuron disease caused by Bi-allelic mutation of survival motor neuron gene 1 (SMN1). There are two identical genes SMN1 (telomeric copy) and SMN2 (centromeric copy) present at human chromosome 5q13. These genes are responsible to synthesize survival motor neuron protein which is necessary for the normal function of motor neurons that control our muscles.

 

Request for :-  spinal muscular atrophy free sample page

Spinal Muscular Atrophy (SMA) Epidemiology  

The Spinal Muscular Atrophy (SMA) epidemiology division provide insights about historical and current Spinal Muscular Atrophy (SMA) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Spinal Muscular Atrophy (SMA) Market Outlook

The Spinal Muscular Atrophy (SMA) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Spinal Muscular Atrophy (SMA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Spinal Muscular Atrophy (SMA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Spinal Muscular Atrophy (SMA) market in 7MM is expected to change in the study period 2017-2030

Report Key facts:-

1. As per Delveinsight analysis, the diagnosed prevalent cases of Spinal Muscular Atrophy in the United Stateswere found to be 11,733 in 2017

2. According to DelveInsight, total prevalent population of Spinal Muscular Atrophy (SMA) in the 7 major marketsranges from approximately 19,343 cases in 2017

3. As per the American College of Obstetricians and Gynecologists, SMN1 is considered the active gene for survival motor neuron protein production, and more than 98% of patients with spinal muscular atrophy have an abnormality in both SMN1 genes, which can be caused by a deletion (95%) of exon 7, or other mutation 

“B. Melissa et al conducted a study titled as “Therapeutic strategies for spinal muscular atrophy: SMN and beyond”, 2017 andstated thatSpinal muscular atrophy (SMA) is the most common genetic disease resulting in death in infancy, affecting approximately 1 in 6000 to 1 in 10,000 births. Therapies that improve neuromuscular function as well as maintain lifelong general health of people living with SMA are therefore a major priority and an unmet clinical need”

Key companies are working on SMA that are given below:- 

1. Hoffmann-La Roche

2. AstellasPharma/Cytokinetics

3. Novartis

Name of drugs are covered are given below:-

1. Risdiplam

2. Reldesemtiv

3. Branaplam

Table of contents

1. Key Insights

2. Executive Summary of Spinal Muscular Atrophy (SMA)

3. Competitive Intelligence Analysis for Spinal Muscular Atrophy (SMA)

4. Spinal Muscular Atrophy (SMA): Market Overview at a Glance

4.1. Spinal Muscular Atrophy (SMA) Total Market Share (%) Distribution in 2017

4.2. Spinal Muscular Atrophy (SMA) Total Market Share (%) Distribution in 2030

5. Spinal Muscular Atrophy (SMA): Disease Background and Overview

6. Patient Journey

7. Spinal Muscular Atrophy (SMA) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Spinal Muscular Atrophy (SMA) Treatment and Management

8.2. Spinal Muscular Atrophy (SMA) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Spinal Muscular Atrophy (SMA) Treatment

11. Marketed Products

12. Emerging Therapies

13. Spinal Muscular Atrophy (SMA): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Spinal Muscular Atrophy (SMA)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Spinal Muscular Atrophy (SMA) market
  • To understand the future market competition in the Spinal Muscular Atrophy (SMA) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Muscular Atrophy (SMA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Spinal Muscular Atrophy (SMA) market
  • To understand the future market competition in the Spinal Muscular Atrophy (SMA) market

Related Reports :- 

1. Spinal Muscular Atrophy (SMA) – Epidemiology Forecast to 2030

2. Spinal Muscular Atrophy Market Insight, Epidemiology and Market Forecast -2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/